DelMar Pharmaceuticals, Inc. (DMPI)

Oncology Corporate Profile

Stock Performance

4.0800
-0.1000

HQ Location

Suite 720 - 999 West Broadway
Vancouver, British Columbia, Canada V5Z 1K5

Company Description

DelMar Pharmaceuticals, Inc. was founded to develop and commercialize new cancer therapies in indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The Company's lead product candidate, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory GBM. VAL-083 has been extensively studied by U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China.

Website: http://www.delmarpharma.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
VAL-083bi-functional alkylating agent3rd line metastatic Glioblastoma Multiforme (GBM)II
VAL-083bi-functional alkylating agentNon Small Cell Lung Cancer (NSCLC)Preclinical
VAL-083bi-functional alkylating agentOvarian cancerPreclinical

View additional information on product candidates here »

Pipeline image

Source


http://www.delmarpharma.com/

Recent News Headlines

DelMar Pharmaceuticals to Participate in Key Opinion Leader Luncheon on Glioblastoma Multiforme Featuring Dr. James Perry, MD

3/2/2017 01:03 pm

[PR Newswire] - VANCOUVER, British Columbia and MENLO PARK, Calif., March 2, 2017 /PRNewswire/ -- DelMar Pharmaceuticals (DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, will participate in a Key Opinion Leader forum highlighting the Company's novel treatment for patients suffering from glioblastoma multiforme ("GBM"). The luncheon forum takes place on Thursday, March 9th at 12:00pm EST at the Lotte New York Palace Hotel in New York City.

DelMar Pharmaceuticals Announces Dosing of the First Patient in Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM)

2/13/2017 01:04 pm

[PR Newswire] - The first patient was dosed by DelMar's collaborators at the University of Texas MD Anderson Cancer Center in Houston Texas. "The dosing of the first subject in this VAL-083 trial marks an important milestone in the advancement of our clinical development program targeting MGMT-unmethylated GBM," said Jeffrey Bacha, chairman & CEO of DelMar Pharmaceuticals.

DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2017 Financial Results

2/13/2017 01:01 pm

[PR Newswire] - VANCOUVER, British Columbia and MENLO PARK, Calif., Feb.13, 2017 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company ...

DelMar Pharmaceuticals, Inc. - "Optimism and Opportunity as we Initiate Clinical Trials for MGMT-unmethylated GBM Patients at MD Anderson"

1/30/2017 02:03 pm

[Accesswire] - NEW YORK, NY / ACCESSWIRE / January 30, 2017 / DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) today published a new blog post on The Chairman's Blog, written by the Company's Chief Executive Officer, Jeffrey ...

DelMar Pharmaceuticals and MD Anderson Initiate New Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM)

1/25/2017 01:03 pm

[PR Newswire] - VANCOUVER, British Columbia and MENLO PARK, Calif., Jan. 25, 2017 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, is pleased to announce the opening of enrollment of a Phase II study of VAL-083 at the University of Texas MD Anderson Cancer Center in Houston, Texas. The Phase II study of VAL-083 (dianhydrogalactitol) in patients with MGMT-unmethylated, Avastin (bevacizumab)-naïve recurrent glioblastoma will enroll 48 patients in a single-arm design to determine if treatment with VAL-083 improves overall survival, compared to historical control. Further information regarding the clinical trial can be found on DelMar's website and at clinicaltrials.gov (clinicaltrials.gov identifier: NCT02717962).

DelMar Pharmaceuticals Receives Additional Non-Dilutive Funding from the Government of Canada to Support Expanded Research with Lead Product Candidate VAL-083

1/9/2017 01:03 pm

[PR Newswire] - VANCOUVER, British Columbia and MENLO PARK, Calif., Jan. 9, 2017 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced an increase in funding of up to CDN$413,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) to support ongoing research with VAL-083.

DelMar Pharmaceuticals, Inc. - "21st Century Cures Act - A Holiday Gift for New Research in the Fight Against Cancer and Other Serious Diseases"

12/19/2016 02:01 pm

[Accesswire] - NEW YORK, NY / ACCESSWIRE / December 19, 2016 / DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) today published a new blog post on The Chairman's Blog, written by the Company's Chief Executive Officer, Jeffrey ...

DelMar Pharmaceuticals Receives Notice of Allowance from the US Patent and Trademark Office for Key Patent for VAL-083

12/14/2016 01:00 pm

[PR Newswire] - "This patent provides DelMar with ownership of essential manufacturing controls required under good manufacturing practice (GMP) guidelines," said Jeffrey Bacha, chairman and CEO of DelMar Pharmaceuticals.

ACCUREXA, INC. (ACXA) and Other Medical Device Companies Add Value for Patients and Investors

11/28/2016 07:00 pm

[Marketwired] - Accurexa, Inc. , a small-cap biotech focused on chemotherapy and immunology, is an up-and-coming leader in the neurological therapy space. Currently, Accurexa is working on the targeted delivery of such ...

DelMar Pharmaceuticals Delivers an Address and Presents an Overview of Upcoming GBM Trials with VAL-083 at the CNS Anticancer Drug Discovery Development Conference and Society for NeuroOncology Annual Meeting

11/21/2016 01:03 pm

[PR Newswire] - VANCOUVER, British Columbia and MENLO PARK, Calif., Nov. 21, 2016 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today summarized the Company's presentations at the CNS Anticancer Drug Discovery and Development Conference and Society for NeuroOncology Annual meeting, which was held November 16-20, 2016 in Scottsdale, Arizona. "It was an honor to be invited to share and discuss our research with leaders in the global neuro-oncology community," stated Mr. Bacha.

DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2017 Financial Results and Corporate Update

11/14/2016 01:03 pm

[PR Newswire] - VANCOUVER, British Columbia and MENLO PARK, Calif., Nov. 14, 2016 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company ...

DelMar Pharmaceuticals Presents New VAL-083 Data at Two International Scientific Conferences

11/7/2016 01:03 pm

[PR Newswire] - VANCOUVER, British Columbia and MENLO PARK, Calif., Nov. 7, 2016 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company ...

DelMar Pharmaceuticals Presents Overview of VAL-083's Unique Anticancer Mechanism at the European Association of Neuro-Oncology (EANO) Annual Meeting

10/17/2016 12:03 pm

[PR Newswire] - VANCOUVER, British Columbia, and MENLO PARK, Calif., Oct. 17, 2016 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, is pleased to announce that the Company presented additional data regarding VAL-083's unique anti-cancer mechanism on Saturday October 15, 2016 at the 12th Meeting of the European Association of Neuro-Oncology (EANO) in Mannheim, Germany. "These data further differentiate VAL-083's mechanism of action against cancer from the current standard of care in the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer," said Dr. Dennis Brown, DelMar's Chief Scientific Officer. Temozolomide, the current front-line therapy generates its anti-tumor activity by methylation of the O6-position of guanine, resulting in a base-pair mismatch which can be lethal to the tumor cell if not repaired. The majority of patients exhibit a high expression of the DNA repair enzyme "MGMT", which readily repairs temozolomide-derived DNA damage leading to tumor resistance and treatment failure. GBM patients failing temozolomide have a very poor prognosis with median survival of 6 – 9 months.

DelMar Pharmaceuticals Announces Upcoming Scientific Conference Presentations

10/13/2016 12:03 pm

[PR Newswire] - VANCOUVER, British Columbia and MENLO PARK, Calif., Oct. 13, 2016 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company ...